Company

About

AAX Biotech

AAX Biotech

Stockholm, Sweden

AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs in antibody-based medicine development. We aim to be a leading partner for the global biopharmaceutical industry focusing on a broad range of diseases including cancer, autoimmune disorders, and neurological conditions. We are committed to providing unparalleled expertise and innovative technologies that contribute to the advancement of novel antibody therapeutics. Technologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.

Innovagen AB

Innovagen AB

IDEON Science Park, Lund, 22370, SE

We focus on development, modification and production of custom antibodies, as well as their antigens; typically synthetic peptides and recombinant proteins. With more than two decades of experience of delivering products and services in the field of molecular biology, we have a complete toolbox of taking a project from idea to finished antibody – and beyond.

Kemwell Biopharma

Kemwell Biopharma

Uppsala, Sweden

Kemwell is a contract biologics development and CMO company providing services to global biopharmaceutical organizations. Kemwell facilities, located in Bangalore, India, are designed and developed with technological support from a leading German pharma company. Kemwell provides customers with cost-effective access to state-of-the-art technology for all mammalian cell culture based products' development and manufacturing. 15,000 sq. m. Kemwell facility consists of a cGMP drug substance manufacturing area with over 4500L bioreactor capacity, sterile fill and finish areas for cGMP drug product manufacturing and process development laboratories to support production of protein therapeutics from mammalian-cell culture – monoclonal antibodies, bi-specific antibodies, fusion proteins, etc. Kemwell is capable of supporting novel, bio-better and biosimilar programs' preclinical development, clinical development, cGMP clinical manufacturing and cGMP commercial manufacturing. Kemwell, having established in 1980, had long term associations with pharma majors such as Bayer, GlaxoSmithKline, Merck KGaA, Novartis, Pfizer and others for small molecule contract mfg. and R&D. In 2016, Kemwell divested its small-molecule division to focus on biologics, leveraging its vast and rich experience. Kemwell is now a 100% biologics CDMO.

Navinci Diagnostics

Navinci Diagnostics

Uppsala, Sweden

Navinci is a Swedish biotech company that specializes in developing innovative solutions for the study of protein interactions. With a focus and a strong legacy in the development of in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth. Our Naveni Proximity Ligation Technology is at the forefront of innovation within the field of spatial proteomics and allows for the detection and quantification of protein interactions and post-translational modifications in a manner that is both sensitive and specific. It provides researchers with a valuable tool for their studies and helps deepen the understanding of the interplay between proteins in their native environment. Our latest focus is on target-specific kits within immuno-oncology, which detect interactions such as PD1/PD-L1. These kits are designed to help researchers easily visualize the interactions between immune checkpoint proteins in immune and cancer cells and elucidate the role that interactions, rather than individual proteins, play in the development of cancer. By providing researchers with reliable and innovative tools for visualizing and interpreting protein interplay, Navinci pushes forward the understanding of cell biology and brings precision to spatial proteomics.

NorthX Biologics

NorthX Biologics

Matfors, Sweden

Recipharm

Recipharm

Stockholm, SE

Recipharm is a leading global CDMO dedicated to meeting your evolving needs through operational excellence, scientific know-how, and customer connectivity. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering. Our worldwide reach paired with in-depth, localised market knowledge allows us to anticipate our customers’ needs and strengthen the support we provide to forge a healthier, more expansive and more fruitful future together. With a workforce of 5 200 people, we are focused on supporting pharmaceutical companies with our full-service offering, taking products from early development through to commercial production. Since our inception in 1995, we have supported our customers throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again to ensure their products are delivered with certainty.

Redoxis

Redoxis

Gotenberg, Sweden

Redoxis is a preclinical boutique CRO specializing on inflammation and autoimmune conditions. We provide in vivo, ex vivo and in vitro preclinical efficacy and MoA studies. We have a fully equipped lab with capacity to perform a wide range of cell based assays as well as immunology assays to provide you everything form MoA studies to PK and in vivo efficacy studies.

TATAA Biocenter

TATAA Biocenter

Göteborg, Sweden

At TATAA Biocenter, we offer PCR bioanalytical services to address the challenges in nucleic acid therapy drug development. Our mission as a CRO is to provide assay development, validation, and high-throughput analyses with high sensitivity for regulated and non-regulated bioanalysis, clinical biomarkers, and manufacturing quality assessments to accelerate your time-to-market. As your extended workbench of specialists and dedicated partner, we prioritize quality, innovation, and building strong client relationships. We are a GLP-accredited, GCLP-compliant, and ISO/IEC 17025-certified laboratory. Our purpose-built facility for nucleic acid analyses enhances sensitivity and minimizes contamination risks. With state-of-the-art instrumentation and an IT structure ensuring the highest data integrity and sample management, our collaborative and highly skilled scientists deliver advanced competence and precise execution.